Druggability & Clinical Context
Druggability
Low
Score: 0.39
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
3
Known Drugs:
1
Approved:
1
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Approved
Therapeutic Areas:Cerebral edema Acute ischemic stroke Traumatic brain injury Neurotoxic brain swelling Glaucoma (aqueous humor regulation) Neurodegenerative diseases with edema component
Druggability Rationale: AQP1 represents a promising druggable target for neurodegeneration due to its role in water transport and potential involvement in neuroinflammatory processes. The availability of high-resolution structural data and existing inhibition strategies like acetazolamide suggest potential for targeted therapeutic intervention, with the channel's precise structural characterization enabling rational drug design approaches. The AlphaFold prediction and multiple PDB structures provide a robust structural framework for understanding potential small molecule binding mechanisms.
Mechanism: AQP1 functions as a water channel protein facilitating transmembrane water flux, with emerging evidence suggesting its involvement in neuroinflammatory processes and potential contribution to neuronal cell volume regulation and edema formation in neurodegenerative conditions. In the context of neurodegeneration, AQP1 may modulate neuronal and glial cell responses to oxidative stress, inflammation, and cellular metabolic perturbations, making it a potential strategic target for therapeutic intervention.
Drug Pipeline (1 compounds)
1 Approved
Known Drugs:Acetazolamide (approved) — Glaucoma, epilepsy, altitude sickness
Structural Data:PDB (3) ✓AlphaFold ✓Cryo-EM ✓
Binding Pocket Analysis:The water-conducting pore features a narrow selectivity filter (~3 Å diameter) with conserved asparagine-proline-alanine (NPA) motifs that coordinate water molecules; modulators likely bind at the pore entrance or allosteric sites flanking the central channel. High-resolution structural data (PDB: 6POJ, 7W7R, 7W7S) enables structure-based design targeting the extracellular or intracellular vestibules where gating can be modulated.
Selectivity & Safety Considerations
AQP1 selectivity is challenging due to the high sequence homology across the aquaporin family (AQP0-AQP12), which could lead to off-target modulation of other water channels. However, structural divergence in the selectivity filter and C-terminus regions provides opportunities for isoform-selective inhibitors to minimize effects on aquaporins involved in other physiological processes.
Clinical Trials (6)
Relevant trials from ClinicalTrials.gov
By Phase
EARLY_PHASE1: 1 · PHASE1: 1 · PHASE3: 1 · PHASE4: 3
PHASE3
NCT05707442
n=74
Idiopathic Intracranial Hypotension, Venous Sinus Stenosis
Interventions: Stent Implantation, Acetazolamide-based medical therapy, Weight loss
Sponsor: Beijing Tiantan Hospital | Started: 2023-02-16
PHASE4
NCT03165890
n=78
Chronic Obstructive Pulmonary Disease (C
Interventions: ACETAZOLAMIDE oral capsule, Placebo oral capsule
Sponsor: University of Zurich | Started: 2017-05-24
PHASE4
NCT05023941
n=252
Acute Mountain Sickness
Interventions: Acetazolamide, Doctormate® (twice daily for 6 days), Doctormate® (forth daily for 3 days)
Sponsor: Ji Xunming,MD,PhD | Started: 2021-12-01
PHASE1
NCT04470843
n=33
Prostate Cancer, Men
Interventions: Acetazolamide, Placebo
Sponsor: Medical College of Wisconsin | Started: 2018-08-22
EARLY_PHASE1
NCT03806751
Validation of a New Noninvasive Method t
Interventions: [O-15]Water, Acetazolamide
Sponsor: University of Alabama at Birmingham | Started: 2025-02-01
PHASE4
NCT02371473
n=12
Central Sleep Apnea, Secondary
Interventions: Acetazolamide-placebo, Placebo-acetazolamide
Sponsor: Shahid Beheshti University of Medical Sciences | Started: 2014-11